Results 11 to 20 of about 31,440 (256)

Tolerability and Effectiveness of Switching to Dulaglutide in Patients With Type 2 Diabetes Inadequately Controlled With Insulin Therapy

Frontiers in Endocrinology, 2022
AimsGlucagon‐like peptide 1 (GLP-1) receptor agonists have demonstrated strong glycemic control. However, few studies have investigated the effects of switching from insulin to GLP-1 receptor agonists.
Youngsook Kim, Ji Hye Huh, Minyoung Lee, Eun Seok Kang, Bong-Soo Cha, Byung-Wan Lee   +5 more
doaj   +1 more source

GLP-1 Receptor Agonists in the Treatment of Patients with Type 2 Diabetes and Chronic Kidney Disease

Kidney and Dialysis, 2022
Diabetic kidney disease (DKD) represents an important diabetes (DM) complication associated with significant impacts on morbidity, mortality, and quality of life. Recent evidence from cardiovascular and kidney outcome trials has dramatically impacted the
Joshua J. Neumiller, Radica Z. Alicic, Katherine R. Tuttle   +2 more
doaj   +1 more source

Glucagon-like peptide 1 and glucose-dependent insulinotropic peptide hormones and novel receptor agonists protect synapses in Alzheimer’s and Parkinson’s diseases

Frontiers in Synaptic Neuroscience, 2022
Glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP) are peptide hormones and growth factors. A major pathological feature of both Alzheimer’s dis-ease (AD) and Parkinson’s disease (PD) is the loss of synaptic transmission ...
Christian Hölscher
doaj   +1 more source

The Road towards Triple Agonists: Glucagon-Like Peptide 1, Glucose-Dependent Insulinotropic Polypeptide and Glucagon Receptor - An Update [PDF]

Endocrinology and Metabolism
Obesity is the fifth leading risk factor for global deaths with numbers continuing to increase worldwide. In the last 20 years, the emergence of pharmacological treatments for obesity based on gastrointestinal hormones has transformed the therapeutic ...
Agnieszka Jakubowska, Carel W. le Roux, Adie Viljoen   +2 more
doaj   +1 more source

Glucagon-Like Peptide 1 Receptor Agonists – Potential Game Changers in the Treatment of Glaucoma?

Frontiers in Neuroscience, 2022
Glaucoma is a common ocular neurodegenerative disease characterized by the progressive loss of retinal ganglion cells and their axons. It is the most common cause of irreversible blindness.
Zaynab Ahmad Mouhammad, Rupali Vohra, Rupali Vohra, Anna Horwitz, Anna-Sophie Thein, Jens Rovelt, Barbara Cvenkel, Barbara Cvenkel, Pete A. Williams, Augusto Azuara-Blanco, Miriam Kolko, Miriam Kolko   +11 more
doaj   +1 more source

GLP-1 receptor agonists for Parkinson's disease

Cochrane Database of Systematic Reviews, 2020
Parkinson's disease (PD) is a progressive disorder characterised by both motor and non-motor problems. Glucagon-like peptide-1 (GLP-1) receptor agonists, licensed for treatment of type 2 diabetes, work by stimulating GLP-1 receptors in the pancreas, which triggers the release of insulin. GLP-1 receptors have been found in the brain.
Caroline A, Mulvaney, Gonçalo S, Duarte, Joel, Handley, David Jw, Evans, Suresh, Menon, Richard, Wyse, Hedley Ca, Emsley   +6 more
openaire   +3 more sources

Adverse Effects of GLP-1 Receptor Agonists [PDF]

The Review of Diabetic Studies, 2014
Glucagon-like peptide-1 (GLP-1) receptor agonists are a class of injective anti-diabetic drugs that improve glycemic control and many other atherosclerosis-related parameters in patients with type 2 diabetes (T2D). However, the use of this relatively new class of drugs may be associated with certain adverse effects.
Theodosios D, Filippatos, Thalia V, Panagiotopoulou, Moses S, Elisaf   +2 more
openaire   +2 more sources

GLP-1 receptor agonists and the risk of thyroid cancer

Diabetes Care, 2022
<p>  </p> <p><em>Objective</em></p> <p>To determine whether the use of GLP-1 receptor agonists (RA) is associated with an increased risk of thyroid cancer.</p> <p><em>Research Design and Methods</em></p> <p>A nested case-control analysis was performed using the French ...
Bezin, Julien, Gouverneur, Amandine, Penichon, Marine, Mathieu, Clément, Garrel, Renaud, Hillaire-Buys, Dominique, Pariente, Antoine, Faillie, Jean-Luc   +7 more
openaire   +3 more sources

Harnessing the Reactivity of Sulfinate Salts With Cystine: An Umpolung Approach to Residue‐Specific Peptide Modification

Angewandte Chemie, EarlyView.
While cysteine is widely employed as a nucleophilic handle for peptide modification, the electrophilicity of the oxidized form, cystine, is rarely exploited. This study describes a mild, photochemical coupling of sulfinate salts with peptide disulfides.
Joshua M. Hammond, Esteban Suárez‐Picado, Lena von Sydow, Hanna Bruss, Laurent Knerr, Magnus Johansson, Anaïs Noisier, Lara R. Malins   +7 more
wiley   +2 more sources

Adverse effects of GLP – 1 Receptor Agonists

Journal of Education, Health and Sport
Introduction and purpose Glucagon-like peptide-1 receptor agonists (GLP – 1 RAs) are indicated in type 2 diabetes (T2D) and obesity because of their high efficacy in controlling blood glucose levels and inducing weight loss.
Anna Kasprzak, Monika Kułaga, Monika Grzybek, Diana Mazur-Lesińska, Barbara Szostak, Sylwia Wielgosz-Biała, Krzysztof Tyszkiewicz, Borys Łozowski, Małgorzata Kasprzak, Barbara Wilczyńska   +9 more
doaj   +1 more source